UK Gastroenterology Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Device Type (Biopsy Forceps, Snares, Injection Needles, Cleaning & Decontamination, EMR/ESD, ERCP, EUS, Others), By End-User (NHS Hospitals, Private Hospitals), and Country Forecast 2020-2031

UK Gastroenterology Devices Market size was valued at US$ 1,230 million in 2024 and is expected to reach US$ 1,750 million by 2031, growing at a significant CAGR of 5.1% from 2025-2031. The British gastroenterology devices market is continually evolving due to increasing demand for increasingly GI disorders and an aging population increasingly exposed to chronic digestive disorders. From colonoscopy equipment to endoscopic ultrasound and capsule endoscopy technology, the sector has a blend of varied technology used to aid timely diagnosis and minimally invasive treatments. In an NHS setting committed to early diagnosis, patient comfort, and effective systems, these devices are increasingly popular in NHS hospitals and private clinics nationwide. Other colorectal cancer screening schemes and elevated awareness of gut health are also driving new diagnostic and treatment device adoption throughout the UK.

Beyond clinical necessity, the market is driven by a combination of technological innovation, procedure convergence, and policy reform in the healthcare space. UK medtech firms and overseas companies are betting on AI-powered endoscopy, wireless capsule imaging, and intelligent biopsy tools for enhanced precision and reduced patient risk. With this, NHS modernization efforts such as digitalization of diagnostic pathways and increased investment in digestive disease programs are creating a favorable atmosphere for the penetration of devices. While regulatory channels post-Brexit continue to be uncertain, UK's emphasis on medicinal innovation and public-private models of healthcare is provision that guarantees the market for gastroenterology devices will be vibrant and rife with opportunities.

Facts & Figures

• UK gastroenterology device demand is being driven by evolving patient attitudes in favor of less invasive and more convenient diagnostic testing.
• NHS physicians and private sector physicians alike are increasingly valuing devices that can make for faster turnaround, efficient processes, and integration with digital diagnostic systems.
• Innovation within the UK market is increasingly being driven through collaborations between medtech firms and healthcare providers, notably for AI-based endoscopy and remote diagnosis.
• Provision purchase decisions are increasingly influenced by the ability of the device to meet NHS efficiency targets, clinician usability, and long-term cost-effectiveness, rather than clinical performance predominantly.    

Key Developments:

• In May 2025, FUJIFILM Healthcare Europe enlarged its ELUXEO® family with the introduction of two premium therapeutic gastroscopes, EG-840T and EG-840TP, to advance precision and dexterity in advanced GI procedures as part of its "WELCOME, FUTURE" program of next-generation endoscopic innovation.
• In March 2025, Creo Medical Group made history in UK endoscopy with the commercial release of its SpydrBlade Flex1, a multi-modal precision device for minimally invasive cancer treatment, echoing an overall trend toward energy-based therapy devices being flexible.
• In October 2024, Olympus obtained CE marking of its cloud-based endoscopy systems with artificial intelligence features, CADDIE, CADU, and SMARTIBD, developed by Odin Vision, marking the increasing use of artificial intelligence to enhance diagnostics and in real-time clinical decision-making.

UK Gastroenterology Devices Market Segmentation:

Based on the device type:

• Biopsy Forceps
• Snares
• Injection Needles
• Cleaning & Decontamination
• EMR/ Esd
• ERCP
• ESU
• Others

Among all the many gastroenterology instruments employed across the UK, biopsy forceps are still one of the most essential instruments applied in diagnostic endoscopy. Gastroenterologists use these instruments more than any others because they are versatile, reliable, and effective at producing high-quality tissue samples in normal and difficult procedures. The instruments are especially crucial in screening protocols for colorectal cancer, where accuracy in procurement is directly related to the diagnosis. These are being refined by makers in an effort to make them more ergonomic, more under grip control, and more suited for high-definition scopes. Their widespread usage in diagnostic and therapeutic use together with greater emphasis on initial mucosal examination favors biopsy forceps as the most consistently utilized form of device used in GI endoscopy procedures.

Based on the end user:

• NHS Hospitals
• Private Hospitals

NHS Trusts rely on increasingly varied configurations of high performance and financially viable equipment in order to facilitate standards of care within their tightly stretched operating budgets. The central purchasing scheme enables economies of scale but, conversely, also engenders high performance expectation, begetting high expectations of simplicity of sterility and reliability. With greater emphasis on day-one diagnostics and backlog clearing since COVID, NHS trusts are seeking medtech solutions that enable procedure efficacy at the expense of clinical performance, making them a key target for medtech innovation and collaboration. By Country – England England leads the market through its high population density of teaching hospitals, advanced endoscope units, and high population awareness of digestive health